Drug-Induced Cancer

  • D. Schmähl
  • M. Habs
Part of the Current Topics in Pathology book series (CT PATHOLOGY, volume 69)


Today more than ever, drug-induced effects and diseases are gaining in significance. Two factors seem to be largely responsible for this development:
  1. 1.

    The number of drugs and their uses are increasing constantly.

  2. 2.

    More and more drugs are being developed which have far-reaching effects on physiologic and pathologic biochemical reactions.



Urinary Bladder Endometrial Carcinoma Natl Cancer Inst Carcinogenic Effect Artificial Sweetener 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson LM, Budinger JM, Maronpot RR, Good RA (1978) Transplacental lung tumorigenesis in the athymic mouse. Cancer Res 38: 137–141PubMedGoogle Scholar
  2. Andrew EJ (1974) Failure of immunosurveillance against chemically induced in situ tumors in mice. J Natl Cancer Inst 52: 729–732Google Scholar
  3. Antunes CMF, Stolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R (1979) Endometrial cancer and estrogen use. Report of a large case-control study. New Engl J Med 300: 9–13PubMedCrossRefGoogle Scholar
  4. Armstrong B, Doll R (1974) Bladder cancer mortality in England and Wales in relation to cigarette smoking and saccharin consumption. Brit J Prev Med 28: 233–240Google Scholar
  5. Armstrong B, Stevens N, Doll R (1974) Restrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet II 672–675Google Scholar
  6. Armstrong B, Lea AJ, Adelstein AM, Donovan JW, White GC, Ruttie S (1976) Cancer mortality and saccharin consumption in diabetics. Brit J Prev Soc Med 30: 151–157Google Scholar
  7. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Idänpään-Heikkilä J (1976) Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: A nationwide case-control study in Finland. Int J Cancer 18: 727–738PubMedCrossRefGoogle Scholar
  8. Aron E (1968) Le traitement medical de la maladie de Dupuytren par un agent cytostatique (methyl-hydrazine). La Presse Medicale 76 (41): 1956PubMedGoogle Scholar
  9. Arseneau JC, Canellos GP, Johnson R, DeVita VT (1977) Risk of new cancers in patients with Hodgkin’s disease. Cancer 40: 1912–1916PubMedCrossRefGoogle Scholar
  10. Baden JM, Kelley M, Wharton RS, Hitt BA, Simmon VF, Mazze RI (1977) Mutagenicity of halogenated ether anesthetics. Anesthesiology 46: 346–350PubMedCrossRefGoogle Scholar
  11. Bailin PL, Tindali JP, Roenigk HH, Hogan MD (1975) Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 232: 359–362PubMedCrossRefGoogle Scholar
  12. Barron CN (1963) Observations on the chronic toxicity of 3-phenyl-5j3-diethylamino-ethyl-1,2,4-oxadiazole in the rat and dog. Exp Molec Path (Suppl) 2: 1–27Google Scholar
  13. Baum JK, Holtz F, Bockstein JJ, Klein EW (1973) Possible association between benign hepatomas and oral contraceptives. Lancet II: 926–929Google Scholar
  14. Bean RHD (1960) Phenylbutazone and leukaemia: A possible association. Brit Med J II: 1552Google Scholar
  15. Beil E, Prechtel K (1973) Malignes Lymphom oder Hydantoin-Lymphadenopathie? Münch Med Wschr 115 (45): 2033–2039PubMedGoogle Scholar
  16. Bengtsson U, Johansson S, Angervall L (1978) Malignancies of the urinary tract and their relation to analgesic abuse. Kidney International 13: 107–113PubMedCrossRefGoogle Scholar
  17. Beyer-Boon ME, DeVoogt HJ, Schaberg A (1.978) The effects of cyclophosphamide treatment on the epithelium and stroma of the urinary bladder. Europ J Cancer 14: 1029–1035Google Scholar
  18. Biancifiori C, Severi L (1966) The relation of isoniazid (INH) and allied compounds to carcinogenesis in some species of small laboratory animals: A review. Brit J Cancer 20: 528–538PubMedCrossRefGoogle Scholar
  19. Bichel J, Bach A (1968) Investigation on the toxicity of small chronic doses of tannic acid with special reference to possible carcinogenicity. Acta Pharmacol Toxicol 26: 41–45CrossRefGoogle Scholar
  20. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De- Lena M, Tancini L, Bajetta E, Musumeci R, Veronesi U (1976) Combination che-motherapy as an adjuvant treatment in operable breast cancer. New Eng J Med 294: 405–410PubMedCrossRefGoogle Scholar
  21. Braun W (1958) Krebs an Haut und inneren Organen, hervorgerufen durch Arsen. Dtsch Med Wschr 83: 870–872PubMedCrossRefGoogle Scholar
  22. Brook CGD (1969) Psychosis in systemic lupus erythematosus (SLE) and the response to cyclophosphamide. Proc Roy Soc Med Vol 62: 28Google Scholar
  23. Burstein N, Mclntire KR (1968) Urethan-induced pulmonary tumors in germ-free mice. Proc Amer Assoc Cancer Res 9: 11Google Scholar
  24. Cadman EC, Capizzi RL, Bertino JR (1977) Acute nonlymphocytic leukemia. A delayed complication of Hodgkin’s disease therapy: Analysis of 109 cases. Cancer 40: 1280–1296PubMedCrossRefGoogle Scholar
  25. Capron JP, Delamarre J, Canarelli JP, Brousse N, Dupas JL (1978) La cholecystecto- mie favorise-t-elle l’apparition du cancer rectocolique? Gastroenterol Clin Biol 2 (4): 383–389PubMedGoogle Scholar
  26. Carter SK, Schabel FM Jr, Broder JE (1972) 1,3-Bis(2-chloroethyl)-l -nitrosourea (BCNU) and other nitrosoureas in cancer treatment. Adv Cancer Res 16: 237–332Google Scholar
  27. Chabner BA (1977) Second neoplasm — a complication of cancer chemotherapy. New Engl J Med 297: 213–214PubMedCrossRefGoogle Scholar
  28. Chalmers TM, MacCarthy DD (1964) Phenylbutazone therapy associated with leukaemia. Brit Med J I: 747Google Scholar
  29. Chaves E (1968) Induction of bladder hyperplasia in rats after a single dose of cyclophosphamide. Rev Franç Études Clin Biol 13: 51–61Google Scholar
  30. Clayson DB (1972) Carcinogenic hazards due to drugs. In: Meyler L, Peck HM (eds) Drug-induced diseases vol 4. Excerpta Medica Monograph, Amsterdam, pp 91–109Google Scholar
  31. Clemmesen J, Hjalgrim-Jensen S (1978) Is phénobarbital carcinogenic? A follow-up of 8078 epileptics. Ecotox Environm Safety 1: 457–470CrossRefGoogle Scholar
  32. Cohen SM, Lower GM, Ertürk E, Bryan GT (1973) Comparative carcinogenicity in Swiss mice of N-[4-(5-nitro-2-furyl)-2-thiazolyl] acetamide and structurally related 5-nitrofurans and 4-nitrobenzenes. Cancer Res 33: 1593–1597PubMedGoogle Scholar
  33. Cohen RJ, Wiernik PH, Walker MD (1976) Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: Report of two cases. Cancer Treatment Rep 60: 1257–1261Google Scholar
  34. Corbett TH (1976) Cancer and congenital anomalies associated with anesthetics. Ann New York Acad Sei 271: 58–66CrossRefGoogle Scholar
  35. Cuatrecasas P (1978) Phenacetin studies. Science 203: 6–7CrossRefGoogle Scholar
  36. Dahm K, DeHeer K (1976) Cancer risk of the stomach resected for ulcer: The role of duodenogastric reflux. Z Krebsforsch 87: 343–344CrossRefGoogle Scholar
  37. Dahm K, Werner B (1973) Anastomosenkarzinom im resezierten Magen der Ratte nach Gabe von N-Methyl-N’-nitro-N-nitrosöguanidin. Dtsch Med Wschr 98: 2486–2487PubMedGoogle Scholar
  38. Dahm K, Werner B (1975) Das Karzinom im operierten Magen. Dtsch Med Wschr 100: 1073–1078PubMedCrossRefGoogle Scholar
  39. Dale GA, Smith RB (1974) Transitional cell carcinoma of the bladder associated with cyclophosphamide. J Urology 112: 603–604Google Scholar
  40. Danielszyk W (1970) Erfahrungen mit Zytostatika bei der multiplen Sklerose. Wien Klin Wschr 82 (40): 697–699Google Scholar
  41. DeHeer K, Werner B (1978) Colonic carcinogenesis in the rat after resection. In: Gerard A (ed) Gastrointestinal tumors. A clinical and experimental approach. Pergamon Press, Oxford New York Toronto Sydney Paris Frankfurt, pp 83–88Google Scholar
  42. Delbrück H, Teillet F, Andrieu JM, Schmitt G, Bayle O, Wetter O (1978) Langzeit-komplikationen bei Patienten mit malignen Lymphomen nach Chemo- und (oder) Strahlentherapie. Dtsch Med Wschr 103: 789–793PubMedCrossRefGoogle Scholar
  43. De Vita VT, Arseneau JC, Sherins RJ, Canellos GP, Young RC (1973) Intensive chemotherapy for Hodgkin’s disease: Long-term complications. In: Natl Cancer Inst Monograph 36, pp 447–454Google Scholar
  44. Douglass D, Levin PT, Moertel CG (1976) Nitrosoureas: Useful agents for the treatment of advances gastrointestinal cancer. Cancer Treatment Rep 60: 757–759Google Scholar
  45. Druckrey H, Preussmann R, Ivankovic S, Schmähl D (1967) Organotrope carcinogene Wirkung bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. Z Krebsforsch 69: 103–201PubMedCrossRefGoogle Scholar
  46. Edmondson HA, Henderson B, Benton B (1976) Liver cell adenomas associated with use of oral contraceptives. New Engl J Med 294: 470–472PubMedCrossRefGoogle Scholar
  47. Ehlers G (1968) Klinische und histologische Untersuchungen zur Frage arzneimittelbedingter Arsen-Tumoren. Z Haut-Geschl-Krkh 43: 763–774Google Scholar
  48. Eisenbrand G, Preussmann R, Sehmähl D (1978) Carcinogenicity of N-nitrosoephedrine in rats. Cancer Letters 5: 103–106PubMedCrossRefGoogle Scholar
  49. Eisenbrand G (1979) Carcinogenic action of BCNU analogs after repeated intraperitoneal application to Sprague-Dawley (SD) rats. Proc Amer Assoc Cancer Res 20: 46Google Scholar
  50. Enderlin F, Guisan Y (1973) Maligne Tumoren unter Immunosuppression, ein neues Problem beim Transplantatempfänger. Helv Chir Acta 40: 773–776PubMedGoogle Scholar
  51. Epstein SS, Andrea J, Joshi S, Mantel N (1967) Hepatocarcinogenicity of griseofulvin following parenteral administration to infant mice. Cancer Res 27: 1900–1906PubMedGoogle Scholar
  52. Fierz U (1965) Katamnestische Untersuchungen über die Nebenwirkungen der Therapie mit anorganischem Arsen bei Hautkrankheiten. Dermatologica 131: 41–58PubMedCrossRefGoogle Scholar
  53. Fiore-Donati L, De Benedictis G, Maiorano G, Chieco-Bianchi L (1961) Development of pulmonary adenomas in mice suckled by mothers receiving urethan. Naturwiss 48: 409–410CrossRefGoogle Scholar
  54. Fox WW (1965) Recent advances in the chemotherapy of tuberculosis. Adv Chemother 2: 197–267PubMedGoogle Scholar
  55. Galy O, Touraine R, Brune J, Roudier P, Gallois P (1963) Le cancer poulmonaire d’origine arsenical des vignerons de Beaujolais. J Fran9 Med Chir Thor 17 (3): 303–311Google Scholar
  56. Gardner WU (1941) The effect of estrogen on the incidence of mammary and pituitary tumors in hybrid mice. Cancer Res 11: 345–358Google Scholar
  57. Gatti RA, Good RA(1971) Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 28: 89–98PubMedCrossRefGoogle Scholar
  58. Gleichmann H, Gleichmann E (1973) Immunosuppression and neoplasia I. A critical review of experimental carcinogenesis and the immunesurveillance theory. Klin Wschr 51: 255–259PubMedCrossRefGoogle Scholar
  59. Goerttler K (1972) Models and facts in iatrogenic cancerogenesis (report). Verh Dtsch Ges Path 56: 138–164Google Scholar
  60. Götz H, Reichenberger M (1972) Ergebnisse einer Fragebogenaktion bei 1670 Dermatologen der Bundesrepublik Deutschland über Nebenwirkungen bei der Griseoful-vintherapie. Hautarzt 23: 485–492Google Scholar
  61. Gottron HA (1954) Gegenwartsfragen beim Hautcarcinom. Med Klin 49: 1553–1560Google Scholar
  62. Gross F (1976) Abschließende Stellungnahme zur Frage eines erhöhten Brustkrebsrisikos durch Rauwolfia-Präparate. Dtsch Ärzteblatt 73: 2370Google Scholar
  63. Guggenheim B (ed) (1979) Health and sugar substitutes. S Karger, Basel München New York SydneyGoogle Scholar
  64. Guisan Y, Enderlin F, Harder F, Brunner F, Thiel G, Bernhardt JP, Schädeli J, Mihatsch M (1973) Malignomas apres transplantation. Schweiz Med Wschr 103: 577–585PubMedGoogle Scholar
  65. Gutjahr P, Spranger J (1975) Acute leukemia following anticancer treatment. J Pediatrics 87: 1004CrossRefGoogle Scholar
  66. Guyer MF, Claus PE (1947) Tumor of the lung in rats following injections of urethane (ethyl carbamate). Cancer Res 7: 342–345PubMedGoogle Scholar
  67. Habs M, Sehmähl D (1976) Influence of five different postnatal lifelong treatments on the transplacental carcinogenicity of ethylnitrosourea in Sprague Dawley rats. Cancer Letters 2: 93–100PubMedCrossRefGoogle Scholar
  68. Habs M, Eisenbrand G, Sehmähl D (1979) Carcinogenic activity in Sprague-Dawley rats of 2-f3-(2-chloroethvl)-3-nitrosoureido]-D-glucopyranose (chlorozotocin). Cancer Letters 8: 133–137PubMedCrossRefGoogle Scholar
  69. Habs M, Sehmähl D (1979) Carcinogenic action od CMF treatment in rats. In: Current chemotherapy. Proc llthlntCongr Chemother II, pp 1711–1713Google Scholar
  70. Habs M, Sehmähl D (1979) Carcinogenic action od CMF treatment in rats. In: Current chemotherapy. Proc llthlntCongr Chemother II, pp 1711–1713Google Scholar
  71. Hamoudi AB, Ertel I, Newton WA, Reiner CB, Clatworthy HW (1974) Multiple neoplasms in an adolescent child associated with IgA deficiency. Cancer 33: 1134–1144PubMedCrossRefGoogle Scholar
  72. Harris CC (1976) The carcinogenicity of anticancer drugs: A hazard in man. Cancer 37 (2): 1014–1023PubMedCrossRefGoogle Scholar
  73. Hartwich G, Butzler W (1971) Zweittumoren bei Hämoblastosen unter zytostatischer Therapie. Med Klin 66 (43): 1445–1450PubMedGoogle Scholar
  74. Heinonen OP, Shapiro S, Tuominen L, Turunen MI (1974) Reserpine use in relation to breast cancer. Lancet II: 675–677Google Scholar
  75. Herbst AL, Ulfelder H, Poskanzer DC (1971) Adenocarcinoma of the vagina: Association of maternal stilboestrol therapy with tumour appearance in young women. New Eng J Med 284: 878–881PubMedCrossRefGoogle Scholar
  76. Herold G, Krause D, Taubert H-D, Baumann R (1979) Das klimakterische Syndrom: Substitutionstherapie mit Östrogenen. Dtsch Ärzteblatt 27: 1814–1815Google Scholar
  77. Hicks RM, Chowaniec J (1977) The importance of synergy between weak carcinogens in the induction of bladder cancer in experimental animals and humans. Cancer Res 37: 2943–3949PubMedGoogle Scholar
  78. Hirohata T, Masuda Y, Horie A, Kuratsune M (1973) Carcinogenicity of tar-containing skin drugs: Animal experiment and chemical analysis. Gann 64: 323–330PubMedGoogle Scholar
  79. Hoover R, Gray LA, Cole P, MacMahon B (1976) Menopausal estrogens and breast cancer. New Engl J Med 295 (8): 401–405PubMedCrossRefGoogle Scholar
  80. Hrushesky W, Sampson D, Murphy GP (1972) Carcinogenicity of ethylmethanesulfonate. J Natl Cancer Inst 49: 1077–1083PubMedGoogle Scholar
  81. Hultengren N, Lagergren C, Ljungrist A (1965) Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand 130: 314–320PubMedGoogle Scholar
  82. Hunstein W, Rehn K (1975) Tumorinduktion durch Zytostatika beim Menschen. Dtsch Med Wschr 100: 155–158PubMedCrossRefGoogle Scholar
  83. Hyman GA, Sommers SC (1966) The development of Hodgkin’s disease and lymphoma during anticonvulsant therapy. Blood 28: 416–427PubMedGoogle Scholar
  84. IARC Monographs on the evaluation of carcinogenic risk of chemicals to man. Some anti-thyroid and related substances, nitrofurans and industrial chemicals. Vol 7, IARC Lyon, pp 85–94 (1974)Google Scholar
  85. Immich H (1974) Assoziation zwischen Reserpin-Medikation und Brustkrebs? Dtsch Ärzteblatt 71 (42): 2997–2999Google Scholar
  86. Isaka H, Yoshii H, Otsuji A, Koike K, Nagai Y, Koura M, Sugiyashu K, Kanabayashi T (1979) Tumors of Sprague-Dawley rats induced by long-term feeding of phenacetin. Gann 70 (1): 29–36PubMedGoogle Scholar
  87. Ivankovic S, Eisenbrand G, Preussmann R (1979) Lung carcinoma induction in BD rats after single intratracheal instillation of an arsenic-containing pesticide mixture formerly used in vineyards. Int J Cancer 24: 786–788PubMedCrossRefGoogle Scholar
  88. Ivankovic S (1979) Personal communicationGoogle Scholar
  89. Jaffe WG (1947) Carcinogenic action of ethyl urethane on rats. Cancer Res 7: 107–112PubMedGoogle Scholar
  90. Jick H, Smith PG (1977) Regularly used drugs and cancer. In: Hiatt HH, Watson JG, Winsten JA (eds) Origins of human cancer. Cold Spring Harbor. A: 389–398Google Scholar
  91. Jick H, Watkins RN, Hunter JR, Dinan BJ, Madsen S, Rothman KJ, Walker AM (1979) Replacement estrogens and endometrial cancer. New Engl J Med 300 (5): 218–222PubMedCrossRefGoogle Scholar
  92. Jochimsen PR, Pearlman NW, Lawton RL (1976) Pancreatic carcinoma as a sequel to therapy of lymphoma. J Surg Oncol 8: 461–464PubMedCrossRefGoogle Scholar
  93. Johansson S, Angervall L (1976) Urothelial changes of the renal papillae in Sprague-Dawley rats induced by long-term feeding of phenacetin. Acta Path Microbiol, Scand A 84: 375–383Google Scholar
  94. Johansson S, Angervall L (1979) Carcinogenicity of phenacetin. Science 204 (4389): 130PubMedCrossRefGoogle Scholar
  95. Juhasz J, Balo J, Kendrey G (1957) Über die geschwulsterzeugende Wirkung des Isonicotinsäurehydrazid (INH). Z Krebsforsch 62: 188–196PubMedGoogle Scholar
  96. Juhasz J, Balo J, Szende B (1963) Neue experimentelle Angaben zur geschwulsterzeugenden Wirkung des Isonicotinsäurehydrazid (INH). Z Krebsforsch 65: 434–439PubMedCrossRefGoogle Scholar
  97. Jung HD (1971) Zur fraglichen Induzierung von Bronchial- und Hautkarzinom durch INH (Isoniazid) am Beispiel der Tuberculosis luposa. Z Erkrank Atmungsorg 135: 31–38Google Scholar
  98. Junghans K, Seufert R, v Gerstenberg L, Ivankovic S (1977) Chemically induced car-cinogenesis in the stomach of the rat after vagotomy and resection. Proc Int Congr Surg Kyoto, JapanGoogle Scholar
  99. Kapadia GJ, Chung EB, Ghosh B, Shukla YN, Basak SP, Morton JF, Pradhan SN (1978) Carcinogenicity of some folk medicinal herbs in rats. J Natl Cancer Inst 60: 683–686PubMedGoogle Scholar
  100. Karchmer RK, Amare M, Larsen WE, Mallouk AG, Caldwell GG (1974) Alkylating agents as leukemogens in multiple myeloma. Cancer 33: 1103–1107PubMedCrossRefGoogle Scholar
  101. Kellet er R, Kuhn D, Schnyder UW, Schröter R (1972) Lymphoretikuläre Hyperplasie nach dreijähriger Methotrexatbehandlung einer Psoriasis. Dtsch Med Wschr 97 (13): 514–516PubMedCrossRefGoogle Scholar
  102. Kessler FJ, Krüskemper HL (1966) Experimentelle Schilddrüsentumoren durch mehr-jährige Zufuhr von Kaliumperchlorat. Klin Wschr 44 (19): 1154–1156PubMedCrossRefGoogle Scholar
  103. Khandekar JD, Kurtides ES, Stalzer RC (1977) Acute erythroleukemia complicating prolonged chemotherapy for ovarian carcinoma. Arch Intern Med 137: 355–356PubMedCrossRefGoogle Scholar
  104. Khandekar JD, Victor TA, Mukhopadhyaya P (1978) Endometrial carcinoma following estrogen therapy for breast cancer. Arch Intern Med 138: 539–541PubMedCrossRefGoogle Scholar
  105. Klatskin G (1977) Hepatic tumors: Possible relationship to use of oral contraceptives. Gastroenterology 73: 386–394PubMedGoogle Scholar
  106. Klein M (1952) The transplacental effect of urethan on lung tumorigenesis in mice. J Natl Cancer Inst 13: 1003–1010Google Scholar
  107. Klein M (1954) Induction of lung adenomas following exposure of pregnant newborn, and immature male mice to urethan. Cancer Res 14: 438–440PubMedGoogle Scholar
  108. Klein M (1966) Influence of age on induction with urethan of hepatomas and other tumors in infant mice. J Natl Cancer Inst 36: 1111–1120PubMedGoogle Scholar
  109. Knoth W (1966) Arsenbehandlung. Arch Klin Exp Dermatol 227: 228–234PubMedGoogle Scholar
  110. Korpassy B (1961) Tannins as hepatic carcinogens. Progr Exp Tumor Res 2: 245–290PubMedGoogle Scholar
  111. Kroes R, Berkvens JM, Weisburger JH (1975) Immunosuppression in primary liver and colon tumor induction with N-hydroxy-N-2-fluorenylaeetamide and azoxymethane. Cancer Res 35: 2651–2656PubMedGoogle Scholar
  112. Labedzki L, Fuchs HJ, Grips KH (1976) Plasmozytom und finale unreifzellige Leukose. Dtsch Med Wschr 101 (4): 108–111PubMedCrossRefGoogle Scholar
  113. Lancet I (1979) Gastric cancer in patients who have taken Cimetidine. Lancet I: 1234–1236Google Scholar
  114. Larsen CD (1947) Pulmonary-tumor induction by transplacental exposure to urethane. J Natl Cancer Inst 8: 63–70Google Scholar
  115. Laska EM, Siegel C, Meisner M, Fischer S, Wanderling J (1975) Matched-pairs study of reserpine use and breast cancer. Lancet II: 296–300Google Scholar
  116. Lee AM, Fraumeni JF (1969) Arsenic and respiratory cancer in man: An occupational study. J Natl Cancer Inst 42: 1045–1052PubMedGoogle Scholar
  117. Leistenschneider W, Ehmann R (1973) Nierenbeckenkarzinom nach Phenazetinabusus. Schweiz Med Wschr 103: 433–439Google Scholar
  118. Lenzin A, Cavalli F, Sonntag R, Zimmermann A (1978) Blasenkarzinom bei langjähriger Behandlung mit Cyclophosphamid wegen multiplem Myelom. Urologie A17: 105–108Google Scholar
  119. Lerner H (1977) Second malignancies diagnosed in breast cancer patients while receiving adjuvant chemotherapy at the Pennsylvania Hospital. Proc Amer Assoc Cancer Res 18: 340Google Scholar
  120. Liebegott G (1949) Pathologische Anatomie der chronischen Arsenvergiftung. Dtsch Med Wschr 27 /28: 855–856CrossRefGoogle Scholar
  121. Liebegott G (1952) Über die Beziehungen zwischen chronischer Arsenvergiftung und malignen Neubildungen. Zbl Arbeitsmed Arbeitsschutz 2: 15–16Google Scholar
  122. Lijinsky W, Taylor HW (1977) Feeding tests in rats on mixtures of nitrite with secondary and tertiary amines of environmental importance. Fd Cosmet Toxicol 15: 269–274CrossRefGoogle Scholar
  123. Lijinsky W, Reuber MD, Blackwell BN (1980) Liver tumors in rats by chronic oral ad-ministration of the antihistaminic methapyrilene hydrochloride. Science 209: 817–819PubMedCrossRefGoogle Scholar
  124. Lindenfelser R (1970) Harnblasenkrebs als Spätfolge chemischer Kampfstoffe. Z Urol 63: 175–177Google Scholar
  125. Lingemann CH (ed) (1979) Recent results in cancer research. Vol 66 Carcinogenic hormones. Springer, Berlin Heidelberg New YorkGoogle Scholar
  126. Lorenz K, Gebert P (1968) Mahgne Retikulose nach Phenylbutazon-Therapie. Münch Med Wschr 110 (40): 2283–2287PubMedGoogle Scholar
  127. Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, Brown SE (1976) Estrogens and endometrial cancer in a retirement community. New Engl J Med 294: 1262–1267PubMedCrossRefGoogle Scholar
  128. McCann CF (1969) Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 8: 209–212CrossRefGoogle Scholar
  129. Meissner WA, Sommers SC, Sherman G (1957) Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. Cancer 10: 500–509PubMedCrossRefGoogle Scholar
  130. Mendelsohn G (1976) Multiple tumors in a renal transplant recipient. John Hopkins ’ Med J 139: 253–256Google Scholar
  131. Meyhöfer W, Knoth W (1966) Über die Auswirkung einer langjährigen antipsoriatischen Arsentherapie auf mehrere Organe unter besonderer Berücksichtigung andrologischer Befunde. Hautarzt 17 (7): 309–313PubMedGoogle Scholar
  132. Minkowitz S (1964) Multiple carcinomata following ingestion of medicinal arsenic. Ann Intern Med 61: 296–299PubMedGoogle Scholar
  133. Mori K, Yasuno A, Matsumoto K (1960) Induction of pulmonary tumors in mice with isonicotinic acid hydrazid. Gann 51: 83–89PubMedGoogle Scholar
  134. Narat JK (1925) Experimental production of malignant growth by simple chemicals. J Cancer Res 9: 135–147Google Scholar
  135. Nettleship A, Henshaw PS, Meyer HL (1943) Induction of pulmonary tumors in mice with ethyl carbamate (urethane). J Natl Cancer Inst 4: 309–319Google Scholar
  136. Neubauer O (1947) Arsenical cancer: A review. Brit J Cancer 1: 192–251PubMedCrossRefGoogle Scholar
  137. Niederle N, Müller H (1978) Harnblasenkarzinom im Verlauf einer chronischen myeloischen Leukämie. Dtsch Med Wschr 103 (34): 1346PubMedGoogle Scholar
  138. O’Fallon WM, Labarthe DR, Kurland LT (1975) Rauwolfia derivatives and breast cancer. Lancer II: 292–296Google Scholar
  139. Osswald H (1968) Prüfung von Kaliumchlorat auf cancerogene Wirkung. Arzneimittel- Forsch 18: 121–122Google Scholar
  140. Ott G (1970) Fremdkörpersarkome. In: Leuthardt F, Schoen R, Schwiegk H, Studer A, Zollinger HU (eds) Exp Med Path Klin. Springer, Berlin Heidelberg New YorkGoogle Scholar
  141. Ott G, Vollmar J, Hieronymi G (1963) Krebsgefährdung nach Implantation von Kunststoffen. Langenbecks Arch Klin Chir 302: 608–628CrossRefGoogle Scholar
  142. Otto H, Plötz D (1966) Experimentelle Tumorinduktion mit Urethanaerosolen. Z Krebsforsch 68: 284–292CrossRefGoogle Scholar
  143. Paris JA (1820) Pharmacologica. 3 Edition. Philips, London, pp 132–134Google Scholar
  144. Peacock A, Peacock PR (1966) The results of prolonged administration of isoniazid to mice, rats, and hamsters. Brit J Cancer 20: 307–325PubMedCrossRefGoogle Scholar
  145. Pearson RM, Soloway MS (1978) Does cyclophosphamide induce bladder cancer? Urology XI (5): 437–447PubMedCrossRefGoogle Scholar
  146. Pein H (1943) Über die Krebsentstehung bei der chronischen Arsenvergiftung. Dtsch Arch Klin Med 190: 429–443Google Scholar
  147. Penn I (1974) Chemical immunosuppression and human cancer. Cancer 34: 1474–1480PubMedCrossRefGoogle Scholar
  148. Penn I, Starzl TE (1972) Malignant tumors arising de novo in immunosuppressed organ transplant recipients. Transplantation 14: 407–417PubMedCrossRefGoogle Scholar
  149. Petersen HS (1973) Erythroleukaemia in a jnelphalan-treated patient with primary macroglobulinaemia. Scand J Hämatol 10: 5–11CrossRefGoogle Scholar
  150. Petri E, Altwein JE (1978) Cyclophosphamide und, Harnblasenkarzinom. Dtsch Med Wschr 103 (1): 30–32PubMedCrossRefGoogle Scholar
  151. Petzoldt D (1966) Stellung und Wert der Arsen-Behandlung aus dermatologischer Sicht. Dtsch Med Wschr 91 (19): 909–910PubMedGoogle Scholar
  152. Pike MC, Edmondson HA, Brenton B, Henderson BE (1977) Liver adenomas and oral contraceptives. In: Hiatt HH, Watson JD, Winsten JA (eds) Origins of human cancer. A Cold Spring Harbor 423–427Google Scholar
  153. Ponomarkov V, Tomatis L, Turusov V (1976) The effect of long-term administration of phenobarbitone in CF-1 mice. Cancer Letters 1: 165–172CrossRefGoogle Scholar
  154. Pool BL (1978) Non-mutagenicity of saccharin. Toxicology 11: 95–97PubMedCrossRefGoogle Scholar
  155. Pool BL (1979) Personal communicationGoogle Scholar
  156. Pool BL (1979) Personal communicationGoogle Scholar
  157. Rassner G (1973) Psoriasis — ihre zytostatische Behandlung und Amethopterin (Methotrexat). Fortschr Med 91 (9): 381–390PubMedGoogle Scholar
  158. Reddy JK, Qureshi SA (1979) Tumorigenicity of the hypolipidemic peroxisome proli- ferator ethyl a-pehlorophenoxy isobutyrate ( Clofibrate) in rats. Br J Cancer 40: 476–482PubMedCrossRefGoogle Scholar
  159. Reimer RR, Hoover R, Fraumeni JF, Young RC (1977) Acute leukemia after alkylating-agent therapy of ovarian cancer. New Engl J Med 297 (4): 177–181PubMedCrossRefGoogle Scholar
  160. Richtmeier AJ (1975) Urinary-bladder tumors after cyclophosphamide. New Engl J Med 293: 1045–1046Google Scholar
  161. Riviere MR, Oberman B, Arnold J, Guerin M (1965) Tumeurs melaniques et melanomes induit chez le Hamster dore par application cutanee de carbamate d’ethyle (urethane). Bull Cancer 52: 127–144Google Scholar
  162. Robson AO, Jelliffe AM (1963) Medicinal arsenic poisoning and lung cancer. Brit Med J II: 207Google Scholar
  163. Rossi L, Ravera M, Repetti G, Santi-L (1977) Long-term ad minist eration of DDT or phenobarbital-Na in Wistar rats. Int J Cancer 19: 179–185Google Scholar
  164. Roth F (1956) Über die chronische Arsenvergiftung der Moselwinzer unter besonderer Berücksichtigung des Arsenkrebses. Z Krebsforsch 61: 287–319PubMedCrossRefGoogle Scholar
  165. Roth F (1957) Arsen — Leber — Tumoren (Haemangioendotheliom). Z Krebsforsch 61: 468–503PubMedCrossRefGoogle Scholar
  166. Rowley JD, Golomb HM, Vardiman J (1977) Acute leukemia after treatment of lymphoma. New Engl J Med 297 (18): 1013PubMedGoogle Scholar
  167. Rumpf P, Schacht U, Palomba P, Kremer K, Schmitz H, Borchard F (1978) Chemisch induzierte Karzinogenese des Rattenmagens nach Vagotomie und Resektion. Z Gastroenterol 16: 85–94PubMedGoogle Scholar
  168. Rupprecht L, Blessing MH (1973) Fibrosarkom der Harnblase nach siebenjähriger Chemotherapie einer Lymphogranulomatose im Kindesalter. Dtsch Med Wschr 98 (36): 1663–1665PubMedCrossRefGoogle Scholar
  169. Rustia M, Shubik P (1976) Transplacental effects of diethylstilbestrol on the genital tract of hamster offspring. Cancer Letters 1: 139–146CrossRefGoogle Scholar
  170. Rustia M, Shubik P (1978) Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment. Brit J Cancer 38: 237–249PubMedCrossRefGoogle Scholar
  171. Saltzstein SL, Ackermann LV (1959) Lymphoadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 12: 164–182PubMedCrossRefGoogle Scholar
  172. Sato T, Utsumi S, Kajikawa K, Ikeda H (1967) A case of cancer of the larynx found in mustard gas poisoning. Jap J Otol 70 (11): 1773–1778Google Scholar
  173. Schabel FM (1976) Nitrosoureas: A review of experimental antitumor activity. Cancer Treatment Rep 60: 665–698Google Scholar
  174. Scherf HR (1972) Untersuchungen an männlichen Sprague-Dawley-Ratten über Zu-sammenhänge zwischen der immundepressiven und der carcinogenen Wirkung bei vier N-Nitroso-Verbindungen. Z Krebsforsch 77: 189–193CrossRefGoogle Scholar
  175. Scherf HR (1976) The effect of 4-dimethylaminoazobenzene and azobenzene on the immune reaction of male Sprague-Dawley rats. Z Krebsforsch 87: 327–332CrossRefGoogle Scholar
  176. Scherf HR, Schmähl D (1975) Experimental investigation on immunodepressive properties of carcinogenic substances in male Sprague-Dawley rats. In: Recent results in cancer research, vol 52: 76–87Google Scholar
  177. Scherf HR, Karsten C, Krüger C (1969) Tierexperimentelle Untersuchungen über im- munsuppressive Wirkungen von Cytostatica. Langenbeck’s ArchChir 325: 1028–1033PubMedCrossRefGoogle Scholar
  178. Scherf HR, Krüger C, Karsten C (1970) Untersuchungen an Ratten über immunosup-pressive Eigenschaften von Cytostatica unter besonderer Berücksichtigung der carinogenen Wirkung. Arzneimittel-Forsch 20: 1467–1470Google Scholar
  179. Scheuer A, Lehmann FG (1977) Lebertumoren bei Therapie mit Kontrazeptiva und Anabolika. Internist 18: 208–214PubMedGoogle Scholar
  180. Schindler AE (1976) Estrogens and endometrial cancer: Aspects of etiology and survival rate. Arch Geschwulst forsch 46 (5): 345–349Google Scholar
  181. Schmähl D (1967) Karzinogene Wirkung von Cyclophosphamid und Triazichon bei Ratten. Dtsch Med Wschr 92 (25): 1150–1152CrossRefGoogle Scholar
  182. Schmähl D (1971) Karzinogenese und Immundepression. Dtsch Med Wschr 96 (45): 1771–1772PubMedGoogle Scholar
  183. Schmähl D (1972) Toxikologische Probleme der iatrogenen Carcinogenese. Verh Dtsch Ges Path 56: 133–138Google Scholar
  184. Schmähl D (1973) Fehlen einer kanzerogenen Wirkung von Cyclamat, Cyclohexylamin und Saccharin bei Ratten. Arzneimittel-Forsch 23: 1466–1470Google Scholar
  185. Schmähl D (1975) Experimental investigations with anti-cancer drugs for carcinogenicity with special reference to immune depression. In: Recent results in cancer research, vol 52. Springer, Berlin Heidelberg New York, pp 18–28Google Scholar
  186. Schmähl D (1977) Carcinogenic action of anticancer drugs with special reference to immunosuppression. Cancer 40: 1927–1929PubMedCrossRefGoogle Scholar
  187. Schmähl D (1978a) Saccharin und Blasenkrebs. Dtsch Med Wschr 103 (3): 91–92PubMedCrossRefGoogle Scholar
  188. Schmähl D (1978b) Experiments on the carcinogenic effect of orthotoluol-sulfonamide (OTS). Z Krebsforsch 91: 19–22CrossRefGoogle Scholar
  189. Schmähl D, Habs M (1976) Life-span investigations for carcinogenicity of some immune-stimulating, immunodepressive and neurotropic substances in Sprague-Daw- ley rats. Z Krebsforsch 86: 77–84CrossRefGoogle Scholar
  190. Schmähl D, Habs M (1978) Experimental carcinogeneses of antitumour drugs. Cancer Treatment Rev 5: 175–184CrossRefGoogle Scholar
  191. Schmähl D, Habs M (1979) Carcinogenic action of low-dose cyclophosphamide given orally to Sprague-Dawley rats in a life-time experiment. Int J Cancer 23: 706–712PubMedCrossRefGoogle Scholar
  192. Schmähl D, Osswald H (1970) Experimentelle Untersuchungen über carcinogene Wirkungen von Krebschemotherapeutica und Immunosuppressiva. Arzneimittel-Forsch 20: 1461–1467Google Scholar
  193. Schmähl D, Reiter A (1954) Fehlen einer cancerogenen Wirkung beim Phenacetin. Arzneimittel-Forsch 4: 404–405Google Scholar
  194. Schmähl D, Wagner R, Scherf HR (1971) Der Einfluß von Immunosuppressiva auf die Cancerisierung der Rattenleber durch Diäthylnitrosamin und die Fibrosarkomentstehung durch 3,4-Benzpyren. Arzneimittel-Forsch 21: 403–404Google Scholar
  195. Schmähl D, Mündt D, Schmidt KG (1974) Experimental investigations on the influence upon the chemical carcinogenesis. 1st communication: studies with ethyl- nitrosourea. Z Krebsforsch 82: 91–100CrossRefGoogle Scholar
  196. Schmähl D, Habs M, Diehl B (1976a) Experimental investigations on the influence upon the chemical carcinogenesis. Und communication: studies with 3,4-benzopyrene. Z Krebsforsch 86: 85–88CrossRefGoogle Scholar
  197. Schmähl D, Danisman A, Habs M, Diehl B (1976b) Experimental investigations on the influence upon the chemical carcinogenesis. Illrd communication: studies with 1,2-dimethylhydrazine. Z Krebsforsch 86: 89–94CrossRefGoogle Scholar
  198. Schmalzl F, Keiser G, Kresbach E, Fritz H, Asamer H, Braunsteiner H (1975) Plasmozytom, Alkylantien und akute myelogene Leukämien. Dtsch Med Wschr 100 (39): 1961–1967PubMedCrossRefGoogle Scholar
  199. Schuermann H (1957) Neuere Therapie der Psoriasis vulgaris universalia. Med Klin 52: 1686Google Scholar
  200. Shimkin MB (1955) Pulmonary tumors in experimental animals. Adv Cancer Res 3: 223–267PubMedCrossRefGoogle Scholar
  201. Smit CG, Meyler L (1970) Acute myeloid leukaemia after treatment with cytostatic agents. Lancer II: 671–672Google Scholar
  202. Sotrel G, Jafari K, Lash AF, Stepto RC (1976) Acute leukemia in advanced ovarian carcinoma after treatment with alkylating agents. Obstet Gyn 47: 67s–71sGoogle Scholar
  203. Swift M, Sholman L, Perry M, Chase C (1976) Malignant neoplasms in the families of patients with ataxia telangiectasia. Cancer Res 36: 209–215PubMedGoogle Scholar
  204. Tannenbaum A, Silverstone H (1958) Urethan (ethyl carbamate) as a multipotential carcinogen. Cancer Res 18: 1225–1231PubMedGoogle Scholar
  205. Taylor HW, Lijinsky W (1975) Tumor induction in rats by feeding aminopyrine or Oxytetracycline with nitrite. Int J Cancer 16: 211–215PubMedCrossRefGoogle Scholar
  206. Thiede T, Christensen BC (1969) Bladder tumours induced by chlornaphazine. Acta Med Scand 185: 133–137PubMedCrossRefGoogle Scholar
  207. Thiers H, Colomb D, Moulin G, Cohn I (1967) Le cancer cutane arsenical des viticulteurs du Beaujolais. Ann Dermatol Syphil 94: 133–158Google Scholar
  208. Thomas C (1972) Systematic of iatrogenic carcinogenesis (report). Verh Dtsch Ges Path 56: 126–132Google Scholar
  209. Toth B (1976) Tumorigenicity of j3-phenylethylhydrazine sulfate in mice. Cancer Res 36: 917–921PubMedGoogle Scholar
  210. Toth B, Boreisha I (1969) Tumorigenesis with isonicotinic acid hydrazide and urethane in the Syrian golden hamster. Europ J Cancer 5: 165–171CrossRefGoogle Scholar
  211. Toth B, Rustia M (1967) The effect of isonicotinic acid hydrazide on the development of tumors. Int J Cancer 2: 413–420PubMedCrossRefGoogle Scholar
  212. Toth B, Tomatis L, Shubik P (1961) Multipotential carcinogenesis with urethan in the Syrian golden hamster. Cancer Res 21: 1537–1541PubMedGoogle Scholar
  213. Trainin N (1963) Neoplastic nature of liver “blood cysts” induced by urethan in mice. J Natl Cancer Inst 31: 1489–1499PubMedGoogle Scholar
  214. Truhaut R (ed) Potential carcinogenic hazards from drugs. Evaluation of risks. UICC Monograph series vol 7. Springer, Berlin Heidelberg New YorkGoogle Scholar
  215. Ulf elder H (1976) The stilbestrol-adenosis-carcinoma syndrome. Cancer 38: 426–431PubMedCrossRefGoogle Scholar
  216. Urman HK, Bulay O, Clayson DB, Shubik P (1975) Carcinogenic effects of niridazole. Cancer Letters 1: 69–74PubMedCrossRefGoogle Scholar
  217. Vesselinovitch SD, Mihailovieh N (1966) Significance of newborn age and dose of urethan in leukemogenesis. Cancer Res 26: 1633–1637PubMedGoogle Scholar
  218. Videbaek A (1964) Chlornaphazine (Erysan) may induce cancer of the urinary bladder. Acta Med Scand 176: 45–50PubMedCrossRefGoogle Scholar
  219. Wada S, Miyanishi M, Nishimoto K, Kambe S, Miller RW (1968) Mustard gas as a cause of respiratory neoplasia in man. Lancet 1: 1161–1163PubMedCrossRefGoogle Scholar
  220. Waldmann TA, Strober W, Blaese RM (1972) Immunodeficiency diseases and malignancy. Various immunologic deficiencies of man and the role of immune processes in the control of malignant disease. Ann Intern Med 77: 605–628Google Scholar
  221. Walker EA, Bogovski P, Griciute L (eds) Environmental N-nitroso compounds. Analysis and formation. IARC Sei Publ No 14, Lyon, FranceGoogle Scholar
  222. Wall RL, Clausen KP (1975) Carcinoma of the urinary bladder in patients receiving cyclophosphamide. New Engl J Med 293: 271–273PubMedCrossRefGoogle Scholar
  223. Waskell L (1978) Study of the mutagenicity of anesthetics and their metabolites. Mutation Res 57: 141–153PubMedCrossRefGoogle Scholar
  224. Waynforth HB, Magee PN (1974) The effect of N-nitroso-N-methylurea and N-dime- thylnitrosamine on cell mediated and humoral immune responses in rats and mice. Brit J Cancer 30: 512–523PubMedCrossRefGoogle Scholar
  225. Weisburger EK (1977) Bioassay program for carcinogenic hazards of cancer Chemother apeu tic agents. Cancer 40: 1935–1949PubMedCrossRefGoogle Scholar
  226. Weiß A, Weiß B (1975) Karzinogenese durch Lost-Exposition beim Menschen, ein wichtiger Hinweis für die Alkylantien-Therapie. Dtsch Med Wschr 100 (17): 923CrossRefGoogle Scholar
  227. Weiß A, Weiß B (1976) Glioblastom und Neurofibrom nach Lost-EinWirkung. Münch Med Wschr 118 (27): 875–878Google Scholar
  228. Weiss NS, Szekely DR, Austin DF (1976) Increasing incidence of endometrial cancer in the United States. New Engl J Med 294: 1259–1262PubMedCrossRefGoogle Scholar
  229. Werner B, DeHeer K, Mitschke H (1977) Cholecystectomy and carcinoma of the colon. Z. Krebsforsch 88: 223–230CrossRefGoogle Scholar
  230. Wildhack R (1973) Leukämie nach Hydantoin-Behandlung. Münch Med Wschr 115 (28): 1275–1279PubMedGoogle Scholar
  231. Williamson RCN, Bauer FLR, Oscarson JEA, Ross JS, Malt RA (1978) Promotion of azoxymethane-induced colonic neoplasia by resection of the proximal small bowel. Cancer Res 38: 3212–3217PubMedGoogle Scholar
  232. Wolfart W (1960) Ruft Isonikotinsäurehydrazid Tumoren hervor? Dtsch Med Wschr 85 (37): 1655–1657PubMedCrossRefGoogle Scholar
  233. Worth PHL (1971) Cyclophosphamide and the bladder. Brit Med J II: 182Google Scholar
  234. Zeller WJ, Schmähl D (1979) Development of second malignancies in rats after cure of acute leukemia L5222 by single doses of 2-ehloroethylnitrosoureas. J Cancer Res Clin Oncol 95: 83–86PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • D. Schmähl
  • M. Habs

There are no affiliations available

Personalised recommendations